ABX
Price
$8.80Alerts
Change
-$0.21 (-2.33%)
Updated
Nov 12, 04:59 PM (EDT)
Capitalization
858.62M
132 days until earnings call
Intraday BUY SELL Signals
JXN
Price
$138.63Alerts
Change
-$0.81 (-0.58%)
Updated
Nov 12 closing price
Capitalization
8.92B
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABX vs JXN

ABX vs JXN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABX vs. JXN commentary
Nov 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABX is a Buy and JXN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABX with price predictions
Nov 12, 2026

ABX in +3.99% Uptrend, growing for three consecutive days on November 10, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABX advanced for three days, in 146 of 208 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABX's RSI Indicator exited the oversold zone, 7 of 10 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ABX as a result. In 60 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

ABX moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABX crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 65%.

The Aroon Indicator entered an Uptrend today. In 95 of 213 cases where ABX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 45%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 58 cases where ABX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 47%.

The 50-day moving average for ABX moved below the 200-day moving average on October 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

ABX broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ABX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.975) is normal, around the industry mean (1.337). P/E Ratio (30.276) is within average values for comparable stocks, (19.773). Projected Growth (PEG Ratio) (0.030) is also within normal values, averaging (0.463). Dividend Yield (0.024) settles around the average of (0.047) among similar stocks. ABX's P/S Ratio (3.453) is very high in comparison to the industry average of (1.303).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.

A.I.Advisor
a Summary for JXN with price predictions
Nov 12, 2026

JXN in upward trend: 10-day moving average moved above 50-day moving average on November 02, 2026

The 10-day moving average for JXN crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 44 of 56 cases where JXN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on JXN as a result. In 71 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for JXN just turned positive on October 22, 2026. Looking at past instances where JXN's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.

JXN moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where JXN advanced for three days, in 290 of 376 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 197 of 269 cases where JXN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where JXN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

JXN broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. JXN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.946) is normal, around the industry mean (1.337). JXN's P/E Ratio (143.141) is considerably higher than the industry average of (19.773). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (0.463). Dividend Yield (0.027) settles around the average of (0.047) among similar stocks. P/S Ratio (1.511) is also within normal values, averaging (1.303).

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
ABX: Fundamental Ratings
ABX
OUTLOOK RATING
1..100
19
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
80
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
65

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABXJXN
RSI
ODDS (%)
Bullish Trend 1 day ago
70%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
47%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
47%
Bullish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
47%
Bullish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 7 days ago
62%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
45%
Bearish Trend 1 day ago
64%
Aroon
ODDS (%)
Bullish Trend 1 day ago
45%
Bullish Trend 1 day ago
73%
COMPARISON
Comparison
Nov 13, 2026
Stock price -- (ABX: $8.78 vs. JXN: $138.63)
Brand notoriety: ABX and JXN are both not notable
Both companies represent the Life/Health Insurance industry
Current volume relative to the 65-day Moving Average: ABX: 74% vs. JXN: 55%
Market capitalization -- ABX: $858.62M vs. JXN: $8.92B
ABX [@Life/Health Insurance] is valued at $858.62M. JXN’s [@Life/Health Insurance] market capitalization is $8.92B. The market cap for tickers in the [@Life/Health Insurance] industry ranges from $228.36K to $140.68B. The average market capitalization across the [@Life/Health Insurance] industry is $18.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABX’s FA Score shows that 0 FA rating(s) are green while JXN’s FA Score has 1 green FA rating(s).

  • ABX’s FA Score: 0 green, 5 red.
  • JXN’s FA Score: 1 green, 4 red.
According to our system of comparison, JXN is a better buy in the long-term than ABX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABX’s TA Score shows that 6 TA indicator(s) are bullish while JXN’s TA Score has 7 bullish TA indicator(s).

  • ABX’s TA Score: 6 bullish, 4 bearish.
  • JXN’s TA Score: 7 bullish, 2 bearish.
According to our system of comparison, JXN is a better buy in the short-term than ABX.

Price Growth

ABX (@Life/Health Insurance) experienced а +0.34% price change this week, while JXN (@Life/Health Insurance) price change was +4.45% for the same time period.

The average weekly price growth across all stocks in the @Life/Health Insurance industry was +0.78%. For the same industry, the average monthly price growth was +1.64%, and the average quarterly price growth was -2.41%.

Reported Earning Dates

ABX is expected to report earnings on Mar 25, 2027.

JXN is expected to report earnings on Feb 24, 2027.

Industries' Descriptions

@Life/Health Insurance (+0.78% weekly)

Life insurance companies mainly sell policies that pay a death benefit as a lump sum upon the death of the insured to their beneficiaries. Life insurance policies may be sold as term life, (which guarantees payment of a stated death benefit and expires at the end of a specified term) or permanent /typically whole life (which is more expensive but lasts a lifetime and carries a cash accumulation component). Life insurance firms may also sell long-term disability policies that help to replace the insured individual’s income if they become sick or disabled. Health insurance, on the other hand, helps pay for medical expenses. Anthem, Inc., MetLife, Inc. and Aflac Incorporated are some of the largest U.S. companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ABX and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABX has been loosely correlated with MET. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ABX jumps, then MET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABX
1D Price
Change %
ABX100%
-2.55%
MET - ABX
37%
Loosely correlated
-1.04%
LNC - ABX
37%
Loosely correlated
-1.79%
PRU - ABX
32%
Poorly correlated
-0.51%
ABXL - ABX
31%
Poorly correlated
-0.08%
JXN - ABX
30%
Poorly correlated
-0.58%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HMH12.530.81
+6.91%
HMH Holding Inc
PSQH1.68N/A
N/A
PSQ Holdings
ARXS53.79-0.58
-1.07%
Arxis Inc
OTTR75.30-2.52
-3.24%
Otter Tail Corp
NVCT20.23-0.77
-3.67%
Nuvectis Pharma